异甘草酸镁治疗失代偿期肝硬化的安全性研究  

Safty research of magnesium isoglycyrrhizinate treatment on patients with decompensated liver cirrhosis

作　　者：王柏芳[1] 王颖[2] 王炳元[1] 温博[1] 高君[1] 

机构地区：[1]中国医科大学附属第一医院老年消化科,沈阳110001 [2]中国医科大学附属第一医院消化内科,沈阳110001

出　　处：《中国肝脏病杂志（电子版）》2014年第2期13-17,共5页Chinese Journal of Liver Diseases：Electronic Version

基　　金：辽宁省科技攻关项目(2011225015);中国肝炎防治基金会天晴肝病研究基金(20120101)

摘　　要：目的：探讨失代偿期肝硬化（DLC）患者应用异甘草酸镁（MIG）注射液保肝治疗的安全性。方法回顾性总结单用MIG或合用其他保肝药物（限2种以内）治疗2周以上、血清离子和血压测定完整的118例DLC患者，男性81例，女性37例，年龄14～84岁，平均年龄（54.6±12.7）岁。其中病毒性肝炎相关肝硬化（VRC）52例，酒精性肝硬化（AC）35例，自身免疫相关肝硬化（ARC）31例。分析治疗1、2周患者血清离子和收缩压（SBP）、舒张压（DBP）的变化。结果 DLC患者治疗1周血清K离子（P =0.015）和Ca离子（P =0.016）均较治疗前增加；其余指标比较，差异均无统计学意义；VRC和AC患者无论是治疗1周还是2周后，所有血清离子改变均无统计学意义；ARC患者治疗1周后，K离子比治疗前在正常范围内略有增加（P=0.043）外，其他指标变化均无统计学意义。DLC和VRC患者治疗1周后，SBP均降低（P =0.007、0.027），DBP无变化；其他两组SBP或DBP均无明显变化。结论无论MIG单用或合用其他保肝药物治疗两周，均没有发现DLC患者水钠潴留和血压升高，短期应用是安全的。Objective To investigate the safty of MIG in anti-inflammatory and hepatoprotective therapy of patients with decompensated liver cirrhosis （DLC）. Methods There are 118 cases with decompensated cirrhosis treated with magnesium isoglycyrrhizinate （80 mg/day） （MIG） alone or combined with other one or two kinds of hepatoprotective drugs treatment above two weeks retrospectively. The blood ions and blood pressure were measured completely, and the male patients were 81 cases and famale patients were 37 cases, while the average age was （54.6 ± 12.7） （14-84） years old. Among total of 118 patients, there were 52 cases of virus-related cirrhosis （VRC）, 35 cases of alcoholic cirrhosis （AC） and 31 cases of autoimmune-related cirrhosis （ARC）. The difference of serum ions and systolic blood pressure （SBP）, as well as diastolic blood pressure （DBP） at the ifrst and second week were tested and analysed. Results To patients on DLC, there was a signiifcant increase in the normal range about blood potassium （P=0.015） and calcium （P=0.016） respectively than that before the therapy, while no increase showed on the other parameters. All the patients on VRC and AC had no meaningful change in serum ions no matter they got on therapy after one week or two. Slight increase showed on blood potassium （P=0.043） of patients with ARC in the normal range after a week’s therapy, while no difference relfected on other parameters signiifcantly. DLC and VRC patients had meaningful reduction on SBP （P=0.007, 0.027） after they went on MIG theray after one week, while no difference on DBP and no signiifcant changes relfected on the other two groups. Conclusions Whether MIG alone or in combination with the other anti-inlfammatory medications about two weeks, observers didn’t ifnd water-sodium retention and blood pressure elevation on the patients with DLC, therefore, short-term treatment of MIG ensures safty.

关 键 词：肝硬化 失代偿期 异甘草酸镁 安全性 

分 类 号：R575.2[医药卫生—消化系统]